[go: up one dir, main page]

EA201992805A1 - Применение 1-[4-бром-5-[1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил]-2-фторфенил]-3-фенилмочевины и аналогов для лечения видов рака, связанных с генетическими нарушениями в рецепторе альфа тромбоцитарного фактора роста - Google Patents

Применение 1-[4-бром-5-[1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил]-2-фторфенил]-3-фенилмочевины и аналогов для лечения видов рака, связанных с генетическими нарушениями в рецепторе альфа тромбоцитарного фактора роста

Info

Publication number
EA201992805A1
EA201992805A1 EA201992805A EA201992805A EA201992805A1 EA 201992805 A1 EA201992805 A1 EA 201992805A1 EA 201992805 A EA201992805 A EA 201992805A EA 201992805 A EA201992805 A EA 201992805A EA 201992805 A1 EA201992805 A1 EA 201992805A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fluorophenyl
dihydro
oxo
ethyl
phenylurea
Prior art date
Application number
EA201992805A
Other languages
English (en)
Inventor
Дэниел Л. Флинн
Майкл Д. Кауфман
Оливер Роузен
Брайан Д. Смит
Original Assignee
ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of EA201992805A1 publication Critical patent/EA201992805A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Настоящее изобретение относится к применению 1-[4-бром-5-[1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил]-2-фторфенил]-3-фенилмочевины или 1-(5-(7-амино-1-этил-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил)-4-бром-2-фторфенил)-3-фенилмочевины при лечении видов рака. В частности, настоящее изобретение направлено на способы ингибирования киназ PDGFR и лечение видов рака и нарушений, связанных с ингибированием киназ PDGFR, включая аденокарциному легкого, плоскоклеточный рак легкого, глиобластому, глиому, свойственную детскому возрасту, астроцитомы, саркомы, стромальные опухоли желудочно-кишечного тракта, злокачественную саркому оболочек периферических нервов, интимальные саркомы, гиперэозинофильный синдром, идиопатический гиперэозинофильный синдром, хронический эозинофильный лейкоз, острый миелоидный лейкоз, связанный с эозинофилией, или лимфобластную Т-клеточную лимфому.
EA201992805A 2017-05-30 2017-05-30 Применение 1-[4-бром-5-[1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил]-2-фторфенил]-3-фенилмочевины и аналогов для лечения видов рака, связанных с генетическими нарушениями в рецепторе альфа тромбоцитарного фактора роста EA201992805A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/035005 WO2018222173A1 (en) 2017-05-30 2017-05-30 Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha

Publications (1)

Publication Number Publication Date
EA201992805A1 true EA201992805A1 (ru) 2020-05-15

Family

ID=59054250

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992805A EA201992805A1 (ru) 2017-05-30 2017-05-30 Применение 1-[4-бром-5-[1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил]-2-фторфенил]-3-фенилмочевины и аналогов для лечения видов рака, связанных с генетическими нарушениями в рецепторе альфа тромбоцитарного фактора роста

Country Status (13)

Country Link
US (5) US20200129489A1 (ru)
EP (1) EP3630110A1 (ru)
JP (3) JP6957650B2 (ru)
KR (3) KR102454978B1 (ru)
CN (1) CN111328283A (ru)
AU (2) AU2017417160B2 (ru)
BR (1) BR112019025346A2 (ru)
CA (1) CA3065365A1 (ru)
EA (1) EA201992805A1 (ru)
IL (1) IL271037A (ru)
MX (1) MX2019014343A (ru)
MY (1) MY205552A (ru)
WO (1) WO2018222173A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2019152719A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
WO2019152711A1 (en) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
KR20210119411A (ko) 2018-12-28 2021-10-05 데시페라 파마슈티칼스, 엘엘씨. 암 치료에 사용하기 위한 csf1r 억제제
MX2021013661A (es) 2019-05-10 2022-03-11 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos.
IL317676A (en) 2019-05-10 2025-02-01 Deciphera Pharmaceuticals Llc Heteroarylaminopyrimidine amides as autophagy inhibitors and methods of using them
BR112021025544A2 (pt) 2019-06-17 2022-05-17 Deciphera Pharmaceuticals Llc Inibidores de autofagia de aminopirimidina amida e métodos de uso dos mesmos
WO2021030405A1 (en) * 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CA3150433A1 (en) * 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CN111171136A (zh) * 2019-12-23 2020-05-19 维塔恩(广州)医药有限公司 肿瘤相关基因PDGFRα突变相关抗原短肽及其应用
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
EP4132571A4 (en) * 2020-04-07 2024-01-17 Hofseth Biocare ASA RESPIRATORY TREATMENTS WITH SALMONIDE OIL COMPOSITIONS
IL299438A (en) * 2020-06-25 2023-02-01 Tolremo Therapeutics Ag A combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for use in the treatment of EGFR-mutated NSCLC
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN101528744A (zh) * 2006-10-20 2009-09-09 Irm责任有限公司 用于调节c-kit和pdgfr受体的组合物和方法
US8461179B1 (en) * 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX372814B (es) * 2012-06-07 2025-03-04 Deciphera Pharmaceuticals Llc Dihidronaftiridinas y compuestos relacionados útiles como inhibidores cinasas para el tratamiento de enfermedades proliferativas.
CN108883108B (zh) * 2016-03-25 2021-08-06 Ab科学有限公司 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途

Also Published As

Publication number Publication date
US20220370424A1 (en) 2022-11-24
KR102454978B1 (ko) 2022-10-17
BR112019025346A2 (pt) 2020-06-30
CN111328283A (zh) 2020-06-23
JP2024001169A (ja) 2024-01-09
KR20230151057A (ko) 2023-10-31
KR20200008598A (ko) 2020-01-28
US20220031678A1 (en) 2022-02-03
IL271037A (en) 2020-01-30
MX2019014343A (es) 2020-08-03
AU2017417160B2 (en) 2024-05-02
JP7365381B2 (ja) 2023-10-19
AU2024205505A1 (en) 2024-08-22
JP2020528875A (ja) 2020-10-01
WO2018222173A1 (en) 2018-12-06
JP2022003080A (ja) 2022-01-11
MY205552A (en) 2024-10-25
JP6957650B2 (ja) 2021-11-02
US20210015801A1 (en) 2021-01-21
CA3065365A1 (en) 2018-12-06
KR20220143152A (ko) 2022-10-24
US20200129489A1 (en) 2020-04-30
US20220370423A1 (en) 2022-11-24
AU2017417160A1 (en) 2019-12-19
EP3630110A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
EA201992805A1 (ru) Применение 1-[4-бром-5-[1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил]-2-фторфенил]-3-фенилмочевины и аналогов для лечения видов рака, связанных с генетическими нарушениями в рецепторе альфа тромбоцитарного фактора роста
Scherpereel et al. Novel therapies for malignant pleural mesothelioma
PH12019550153A1 (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
Sun et al. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
JP2019527706A5 (ru)
MX2024002838A (es) Metodos para tratar trastornos usando inhibidores de csf1r.
Gamie et al. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
PH12022551486A1 (en) Compounds and methods for the targeted degradation of androgen receptor
EA202091761A1 (ru) Комбинированная терапия для лечения гастроинтестинальных стромальных опухолей
JP2013166763A5 (ru)
CY1124456T1 (el) Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων
AU2015314007B2 (en) Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
EA202091514A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR
RU2016113757A (ru) Комбинированная терапия на основе антител против человеческого csf-1r и антител против человеческого pd-l1
NZ741936A (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MX2018012457A (es) Terapia combinatoria con inhibidores notch y cdk4/6.
EA202192796A1 (ru) Tigit и pd-1/tigit-связывающие молекулы
BR112022011998A2 (pt) Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
MX2024000614A (es) Anticuerpos anti-fgfr2 combinados con quimioterapia para el tratamiento del cancer.
JP2018536682A5 (ru)
GB2518908A (en) Materials and methods for treating PTEN mutated or deficient cancer
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
MX2021002241A (es) Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1).
JP2014523421A5 (ru)